CABs
Community advisory boards (CABs) are community engagement platforms, comprised of treatment advocates and community leaders with lived experience to review the state of treatment research, contribute to research protocols, engage in the research and development process, and meet with industry and developers about cost, pricing, and access plans.
HCV World CAB (2014-2017)
The HCV World CAB interacted with pharmaceutical and diagnostics companies that produce HCV treatment and tests to understand their access, licensing, and pricing strategies, particularly in high-burden, low- and middle-income countries.
First HCV World CAB Meeting
Treatment activists held the first global LMIC-focused dialogue with pharmaceutical companies that produce HCV treatment, co-organized by TAG and the Asia Pacific Network of PLHA. More
LAT CAB (2021-present)
Funded by the Unitaid LONGEVITY project, the LAT CAB is a new cross-disease long-acting technologies (LAT) community advisory board focused on malaria, the hepatitis C virus, HIV, and latent TB infection.
About
LAT CAB reviews the state of treatment research, contributes to research protocols, and engages in the research and development process for long-acting technologies for malaria, HCV, HIV, and LTBI. More
Preferences and Feasibility of Long-Acting Technologies for the Treatment of Hepatitis C - A Survey of Patients
A study explores the challenges and opportunities in long-acting HCV treatment across three LMICs: Egypt, Ethiopia and India. More
